Second-generation Thyrotropin Receptor Antibodies Assay and Quantitative Thyroid Scintigraphy in Autoimmune Hyperthyroidism

Abstract

Graves' disease (GD) is characterized by circulating TSH receptor antibodies (TRAb), and so-called hyperthyroid autoimmune thyroiditis (H-AIT) generally shows negative TRAb results with first-generation assays. However, a positive titer was observed in up to 13% of patients with euthyroid or hypothyroid autoimmune thyroiditis (AIT) by second-generation TRAb assays, and a larger increase is expected in hyperfunctioning forms. A thyroid 99mTc-pertechnetate uptake (TcTUs) cutoff of 2% previously was shown to accurately discriminate between GD and H-AIT. Here we evaluated the relationship between second-generation TRAb assays and TcTUs in 139 patients with untreated autoimmune hyperthyroidism. An increase in TRAb levels was found in 114 of 139 patients (82%). All patients with TcTUs >2% and 66% of those with lower values had positive TRAb measurements. When the cutoff was increased to 5.9 U/l, positive TRAb occurred in 92.6% of those having higher TcTUs and in 1.4% of those with lower TcTUs. TRAb levels significantly increased in patients with TcTUs higher than 2% as compared with those having lower values, while no differences occurred in patients with TcTUs ranging from 0 to 1%, from 1.1 to 1.5%, or from 1.6 to 2%. A significant relationship between TRAb and TcTUs (as well as fT3, fT4, and thyroid volume) was found. TcTUs, fT4, fT3, and thyroid volume significantly increased in patients with positive TRAb (cutoff 1.5 U/l) compared with those testing negative. Our data indicate that a large proportion of patients with hyperthyroidism and hypoechoic thyroid, including those previously diagnosed as having H-AIT, actually have circulating TRAb. TRAb levels predicate the degree of iodine uptake (as measured by TcTUs) and thyroid hyperfunction. The role of baseline TRAb measurement by second-generation assays to predict patients’ outcome needs to be further evaluated and compared with TcTUs in prospective studies.

Key words

thyrotropin receptor antibodies - hyperthyroidism - quantitative thyroid scintigraphy - radio-receptor assay - 99mTc-pertechnetate

References

• 1 Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vikmo H. The value of ultrasonography in predicting autoimmune thyroid disease.  Thyroid. 2000;  10 251-259
• 2 Sinclair D. Clinical and laboratory aspects of thyroid autoantibodies.  Ann Clin Biochem. 2006;  43 173-183
• 3 Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE. Binding, stimulating and blocking antibodies to the thyrotropin receptor as predictors of relapse of Graves’ disease after withdrawal of antithyroid treatment.  Horm Metab Res. 2005;  37 745-750
• 4 Pearce EN, Farwell AP, Bravermann LE. Thyroiditis.  N Engl J Med. 2003;  348 2646-2655
• 5 Meller J, Becker W. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound.  Eur J Nucl Med. 2002;  29 ((Suppl 2)) 425-438
• 6 Giovanella L, Ceriani L, Garancini S. Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves’ disease. Evaluation in patients with negative 1st generation test.  Clin Chem Lab Med. 2001;  39 25-28
• 7 Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D. et al . Second generation assay for thyrotropin receptor antibodies has superior sensitivity for Graves’ disease.  J Clin Endocrinol Metab. 1999;  84 90-97
• 8 Meller J, Schreivogel I, Bergmann , Morgenthaler N, Hüfner M, Becker W. Klinische Implikationen eines neuen TSH-Rezeptor-Antikoerper-Assays (DYNOtest-TRAKhuman) bei autoimmunen Schilddrüsenerkrankungen.  Nuklearmedizin. 2000;  39 14-18
• 9 Paunkovic J, Paunkovic N. Does autoantibody-negative Graves’ disease exist? A second evaluation of the clinical diagnosis.  Horm Metab Res. 2006;  38 53-56
• 10 Sahlmann CO, Siefker U, Lehmann K, Harms E, Conrad M, Meller J. Quantitative thyroid scintigraphy for the differentiation of Graves’ disease and hyperthyroid autoimmune thyroiditis.  Nuklearmedizin. 2003;  43 124-128
• 11 Andermann P, Schlogl S, Mader U, Luster M, Lassmann M, Reiners C. Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound.  Nuklearmedizin. 2007;  46 1-7
• 12 Schott M, Eckstein A, Willenberg HS, Nguyen TBT, Morghenthaler NG, Scherbaum WA. Improved prediction of relapse of Graves’ thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.  Horm Metab Res. 2007;  39 56-61
• 13 Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves’ disease.  Eur J Endocrinol. 2002;  146 173-177
• 14 Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, Mozai T. et al . Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves’ disease.  Arch Intern Med. 1984;  100 372-375

Correspondence